- Home
- RTO vs EXEL Comparison
RTO vs EXEL Comparison
Compare RTO & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RTO | EXEL |
|---|---|---|
| Founded | 1925 | 1994 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7B | 11.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | RTO | EXEL |
|---|---|---|
| Price | $28.44 | $44.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 24 |
| Target Price | N/A | ★ $44.73 |
| AVG Volume (30 Days) | 812.9K | ★ 2.5M |
| Earning Date | 01-21-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | 0.13 | ★ 2.38 |
| Revenue | ★ $7,581,860,530.00 | $2,288,218,000.00 |
| Revenue This Year | $48.64 | $9.14 |
| Revenue Next Year | $3.22 | $12.51 |
| P/E Ratio | $42.11 | ★ $18.67 |
| Revenue Growth | N/A | ★ 9.93 |
| 52 Week Low | $19.60 | $31.90 |
| 52 Week High | $30.10 | $49.62 |
Technical Indicators
Market Signals| Indicator | RTO | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 64.06 | 63.52 |
| Support Level | $27.47 | $43.00 |
| Resistance Level | $28.65 | $44.79 |
| Average True Range (ATR) | 0.38 | 1.03 |
| MACD | 0.18 | 0.06 |
| Stochastic Oscillator | 92.15 | 83.48 |
Price Performance
Historical ComparisonAbout RTO Rentokil Initial plc
Rentokil Initial is the largest global provider of route-based pest control and commercial hygiene services, operating in 89 countries. The group also offers a range of specialist route-based services, including office and commercial space plant care, property care, and workwear rentals. The group serves a diverse client base of global food producers, hotel chains, industrial goods companies, restaurants, and individual residential customers.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.